Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2409 Safety and PK in Rheumatoid Arthritis
NCT02171143Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2012
- Primary completion
- Apr 2014
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing ASP2409 Dose Escalation with Placebo Dose Escalation (2 arms). Primary endpoints: Area under the concentration-time curve from time 0 to last quantifiable concentration, Area under the concentration-time curve extrapolated to infinity and 7 more. Started Apr 2012; status: completed.
02
Drugs
ASP2409
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02171143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171143.